HDAC9 deficiency promotes tumor progression by decreasing the CD8⁺ dendritic cell infiltration of the tumor microenvironment

Abstract

HDAC9 deficiency decreased inflammation and promoted tumor progression by decreasing CD8⁺ DC infiltration of the TME. HDAC9 expression in the tumor stroma may represent a promising biomarker to predict the therapeutic responses of patients receiving CD8⁺ T cell-dependent immune treatment regimens.